|
|
||||||||
Translocation to the T Cell Plasma Membrane1








* Departments of Medicine and Pediatrics, University of California, San Diego, CA 92093 and IACOPO Institute for Translational Medicine, San Diego/Utrecht;
La Jolla Institute for Allergy and Immunology, San Diego, CA 92121;
Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92121;
Androclus Therapeutics, Milan, Italy;
¶ Department of Pediatric Immunology, Wilhelmina Childrens Hospital, University of Utrecht, University Medical Center Utrecht, Utrecht, The Netherlands;
|| Benaroya Research Institute, Virginia Mason, Seattle, WA 98101; and
# Torrey Pines Institute for Molecular Studies, San Diego, CA 92121
| Abstract |
|---|
|
|
|---|
, a T cell signaling molecule that colocalizes with the TCR within the supramolecular activation cluster, thus indicating efficient engagement of T cell activation pathways. Engineered aAPC may have immediate application for basic and clinical immunology studies pertaining to modulation of T cells ex vivo. | Introduction |
|---|
|
|
|---|
Previously, we described artificial APC (aAPC) in which MHC-peptide complexes were randomly distributed within the aAPC membrane (16, 17). These aAPC were prepared by inserting affinity-purified MHC molecules containing their transmembrane domain in highly fluid lipid bilayers. Such aAPC were very efficient in identifying class II-restricted Ag-specific T cells but their capacity to effectively stimulate T cells was limited to some high-affinity T cell hybridomas which do not require costimulation. As also suggested by elegant work from others (18), using similar technology, suboptimal stimulatory capacity was presumably due to the combination of several factors, including inappropriate orientation of MHC molecules, lack of organization, and insufficient local concentration of T cell ligands in the area of contact between the aAPC and T cell. Taken together, these data show that the efficiency of these artificial systems in inducing T cell activation may be influenced by the relative density of MHC-peptide complexes available at the point of interaction.
The concept that high relative density of T cell ligands may affect optimal stimulation was further corroborated by findings suggesting that MHC-peptide complexes are clustered on the surface of APC even in the absence of T cells (19, 20, 21, 22, 23). Disruption of these discrete microdomains (MDs) reduced the efficiency of natural APC in inducing T cell activation (19). This seems to be particularly true when polyclonal, lower affinity T cells are used.
We compared here two systems of aAPC, one in which MHC-peptide complexes were uniformly distributed on the aAPC surface and another in which MHC-peptide complexes were clustered in MDs on the aAPC surface and designated here as MDaAPC. The two types of aAPC were tested for their capability to induce ex vivo activation of human polyclonal Ag-specific CD4+ T cells. The efficiency of activation by the two types of aAPC was compared with stimulation assays using natural APC or tetramers. We also explored whether migration of protein kinase C
(PKC
) to the SMAC could be induced by MDaAPC, thus indicating engagement of physiological pathways of T cell activation.
Altogether, our study in two completely artificial systems underscores the advantages of mimicking the naturally patchy distribution of T cell ligands on APC membranes to efficiently manipulate T cells. This technology provides a viable tool for the modulation and expansion ex vivo of Ag-specific T cells which are difficult to expand or may be scarcely represented. There are immediate implications for this approach for basic research as well as for clinical applications, such as cell therapy of immunodeficiencies and cancer.
| Materials and Methods |
|---|
|
|
|---|
Micelles were prepared from phosphatidylcholine (Sigma-Aldrich) and cholesterol (Sigma-Aldrich) in a molar ratio of 7:2, respectively. Lipids, dissolved in chloroform were dried under nitrogen and resuspended at 10 mg/ml in 140 mM NaCl and 10 mM Tris-HCl containing 0.5% sodium deoxycholate (Sigma-Aldrich) at pH 8.0. Monosialoganglioside GM1 (Sigma-Aldrich) was added at a final concentration of 0.28 or 0.55 mM. Before use, samples were sonicated and dialyzed against PBS for 48 h at 4°C.
Assembly of MDaAPC
MDaAPC were assembled by combining biotinylated Abs and MHC-peptide complexes with biotinylated cholera toxin B (CTB; Sigma-Aldrich) in a 3:1 molar ratio. Neutravidin (NA; Pierce) was added at a ratio of 1 mol of NA per 4 biotinylated moiety. After 15 min of incubation at room temperature (RT), the liposomes were added. This structure ensures proper orientation of T cell ligands. The number of GM1 sites available for binding by CTB subunits was determined by FACS. These corresponded closely to the calculated available sites based on the synthesis of the GM1-liposome. Several experiments were performed by sequentially adding the MD components to the liposomes and measuring binding by FACS. The GM1-containing liposomes bound either FITC-conjugated CTB or biotinylated CTB, visualized by streptavidin-CyChrome (BD Pharmingen). This binding could be blocked by preincubation with nonfluorescent avidin block (data not shown). To establish the optimal ratio between GM1 and TCR ligands in the MDs, a titration curve with different concentrations of anti-CD3 Ab or MHC/peptide was made. By using different CTB:GM1 molar ratios in a range from 1:0.1 to 1:100, the highest rate of binding was achieved with a molar ratio of 1:50 CTB:GM1. DRB1*0701 molecules were purified from a homozygous HLA-DRB1*0701 human B cell line by affinity chromatography (AminoLink-Pierce coupled with LB3.1 Ab from HB298 ATCC) as previously described (16). Affinity-purified DRB1*0701 molecules were biotinylated at the C terminus (EZLink Biotin-LC-PEO-Amine; Pierce); efficiency of biotinylation was measured spectrophotometrically using HABA avidin reagent (Sigma-Aldrich). The recombinant biotinylated HLADRB1*1101 molecule was purified from transfected S2 cells (24, 25). Binding of hemagglutinin (HA) 307319 peptide to affinity-purified DRB1*0701 was performed for 72 h at RT; MHC-peptide binding parameters were previously optimized (16). Binding of HA307319 peptide with recombinant HLA-DRB1*1101 molecules was performed according to Kwoks protocol (24). Efficiency of binding between T cells and aAPC was measured by FACS as the percentage of the total CD4+ T cells bound to the aAPC. This was visualized by labeling the aAPC with FITC-conjugated CTB before incubation with PBMC.
Evaluation of aAPC size by FACS
The average size of the liposomes was evaluated by comparison with yellow-green fluorescent beads of known size with diameters ranging between 0.1 and 1.0 µm (Fluoresbrite Micro particles; Polysciences). Liposomes particles were incubated with biotinylated CTB, which binds the GM1 moieties, washed, and then labeled with CyChrome-conjugated streptavidin. Liposomes were washed by centrifugation at 13,000 x g for 10 min at RT. Samples were prepared by mixing a known volume of the CyChrome-labeled liposomes with a known number of the Fluoresbrite Micro beads of different sizes (0.5, 0.75, and 1.0 nm in diameter). The samples were then acquired by FACS with the beads visualized in the FL1 channel and the streptavidin-CyChrome-labeled liposomes in the FL3 channel. The samples were counted for exactly 20 s and the liposome:bead ratio was calculated. Using this ratio, it was possible to obtain the number of liposome particles in 1 ml of the original sample by using the formula provided by the kit: number of particles per milliliter = 6W x 1012/rxpxf3, where W = grams of polymer, r = density of polymer in grams per milliliter, p = 3.1417, and f = diameters in micrometers of latex micro particles.
Preparation of tetramers
MHC-peptide tetramers were assembled using recombinant biotinylated HLA-DRB1*1101 molecules or affinity-purified biotinylated DRB1*0701 molecules, complexed with HA307319 peptide. Tetramers were formed by cross-linking of biotinylated DRB1*0701/HA307319 or biotinylated HLA-DRB1*1101-HA307319 complexes with NA and incubating for 2 h at RT (Pierce). The NA-MHC/peptide complex molar ration was 1:8, to ensure the occupancy of the four biotin binding sites of NA (24, 25).
Ex vivo stimulation of CD4+ T cells
CD4+ T cells were sorted from total PBMC using influenza-immunized donors with a FACSVantage cytometer (BD Biosciences). For each sample, 2.5 x 105 CD4+ T cells were incubated for 60 h in RPMI 1640 containing 10% human Ab serum at 37°C in different stimulating conditions. For polyclonal T cell stimulation, cells were added to aAPCs carrying 45 pmol of anti-CD3 Ab alone or in combination with 45 pmol of anti-CD28 Ab on raft; aAPC with the same picomoles of anti-CD28 Ab or anti-CD19 Ab, loaded on rafts, were used as controls. CD4+ T cells were also incubated in the presence of anti-CD3-coated beads (anti-CD3 MicroBeads MACS; Miltenyi Biotec) plus soluble purified anti-CD28 Ab (2 µg/ml; BD Pharmingen) or in 96-well plates coated with anti-CD3 plus soluble anti-CD28. The amounts of beads and Abs for the controls were calculated to stimulate the cells with the same picomoles of anti-CD3 and anti-CD28 Abs loaded on the aAPC (45 pmol for 2.5 x 105 cells).
For Ag-specific T cell stimulation, 2.5 x 105 sorted CD4+ T cells were incubated for 60 h with aAPC carrying 125 pmol of biotin-DRB1*0701/or biotin-HLA-DRB1*1101/HA307319 complexes on MD alone or in combination with 75 pmol of anti-CD28 Ab at 37°C. As controls, aAPC with the same number of moles of anti-CD28 Ab or anti-CD19 Ab, loaded on rafts, were used. Stimulation was also induced by incubating CD4+ T cells with aAPC containing MHC-peptide complexes randomly distributed in the membrane. In this case, 125 pmol of the same MHC-peptide complexes without biotinylation were directly inserted and uniformly distributed on the aAPC surface (16).
For stimulation with tetramers, after cross-linking of the biotinylated MHC/peptide with NA, the tetramer solution was directly added to 2.5 x 105 sorted CD4+ T cells and incubated for 60 h at 37°C.
After stimulation, cells were stained with PE-conjugated anti-CD69 mAb (BD Pharmingen) or permeabilized, fixed, and stained with PE-conjugated anti-IL-2 mAb (BD Pharmingen). Analysis was performed with CellQuest software (BD Biosciences).
Ex vivo stimulation of human HA307319-specific human T cell line by MDaAPC or natural APC
The immortalized human T lymphoid cell line CH7C17 was cultured for 10 days in a selection medium. The V
3 TCR of the CH7C17 cell line was stained every 3 days with mouse anti-human TCR V
3 FITC (Serotec) to analyze the expression of the V
3 TCR
EBV HLA-DR1 B cells from a homozygous patient were cultured in U-bottom wells at 2.0 x 105 cells/well for 120 h with or without Ags OVA323339 and HA307319 (40 µg/ml). The EBV cells were irradiated (10,000 rad) after 120 h. MDaAPC were prepared as above (26). CH7C17 T cells were incubated with MDaAPCs or natural APC for 60 h at 37°C in the presence of CO2. CH7C17 T cells/APC were cultured at the ratio of 1:1 in the presence of IL-2 (0.8 µl per 200-µl U-bottom well). C7CH17 T cells were incubated with MDaAPC as described above (26). Expression of CD69 was assessed by FACS (FACSCalibur; BD Biosciences) using standard procedures.
Visualization of PKC
translocation and measurement of liposomes by confocal fluorescence microscopy
FACS-sorted CD4+ T cells were incubated with aAPC for 20 min and then placed on a poly-L-lysine-coated glass slide, fixed, permeabilized, and stained with polyclonal anti-PKC
Ab (Santa Cruz Biotechnology). After washing in 1% BSA in PBS, samples were incubated with a secondary Ab coupled with Alexa 594 (Molecular Probes) and washed again. After the final wash, cells were mounted using a drop of Aqua-Poly/mount (Polysciences). Samples were viewed with a Plan-Apochromat x63 lens on a Nikon microscope. Images were taken using the Bio-Rad MRC 1024 laser scanning confocal imaging system. To determine the size of liposomes, a Jurkat T cell mutant, CH7C17, was used (27). Cells were treated as described above. Single-frame confocal images were obtained by confocal videomicroscopy (LSM 410; Zeiss) using a x40 lens and x4 zoom for a 64-s scanning time. For measurement purposes, an Improved Neubauer hemacytometer (Reichert) was used, visualizing a square of 5-µm size.
Measurement of PKC
capping area
The area of PKC
translocation was measured by drawing a circle around each cell and around high-density pixel areas identified by the software using standard settings. Such high-density areas corresponded to PKC
patches. The ratio between the outlined areas was calculated using a MetaMorph Imaging System, version 3.5 (Universal Imaging). The area of each PKC
patch was expressed as a percentage of the whole cell area. Evaluation was performed by a blinded observer.
Statistics
Analysis of statistical significance was performed by using the Students t test and calculation of linear regression and correlation coefficients between the percentage of IL-2-producing or the percentage of CD69-expressing T cells, and the immune synapse areas was calculated with Apple Works 6 (Apple) and Primers of Biostatistic software.
| Results |
|---|
|
|
|---|
We have previously described aAPC in which MHC-peptide complexes were randomly distributed within the bilayer membrane (16, 17, 28). In aAPC tested here (MDaAPC), MHC-peptide complexes and accessory molecules were organized into MDs within the aAPC surface.
Figure 1a shows a scheme of the minimum MD unit. Average size for MDaAPC was determined to be in the range between 100 and 1000 nm by confocal microscopy (Fig. 1b) and was confirmed by comparison to beads of known size by FACS analysis. To achieve a very high density of T cell ligands, we engineered MDaAPC to take advantage of the binding of CTB to ganglioside GM1, a component of lipids rafts in natural membranes (29, 30). GM1-containing liposomes were loaded with a preassembled tetravalent structure consisting of NA core complexes with biotinylated T cell ligands (e.g., anti-CD3 Ab or MHC-peptide complexes and anti-CD28 Abs). This structure was then anchored at the GM1/cholesterol-enriched areas of the liposome bilayer through a biotinylated CTB unit. All of the components of this aAPC were titrated to test the functionality of the system. This structure ensures appropriate orientation of the molecules involved. This represents a significant improvement over several similar technologies, including our own previously described aAPC. Each aAPC contained
8 x 107 molecules of sialo-GM1 ganglioside. At this concentration, the addition of GM1 at 2.55 molar % to phosphatidylcholine/cholesterol mono- or bilayered artificial membranes leads to the formation of discrete submicrometer-sized round domains (2.5-nm thick), analogous to those found in detergent-insoluble membrane fractions. The addition of CTB increases the domain thickness to 67 nm, indicating an interaction of CTB subunits with GM1 hydrophilic residues on the membrane surface (31, 32).
|
Engineered aAPC are efficient in T cell stimulation in vitro
We first evaluated the efficiency of MDaAPC to induce Ag-independent activation of CD4+-sorted polyclonal T cells. Stimulation of FACS-sorted CD4+T cells with aAPC carrying anti-CD3 and anti-CD28 Abs on MD was compared with stimulation of the same CD4+ T cells by anti CD3-coated beads or by anti-CD3-coated plates plus soluble anti-CD28 (Table I). A significantly higher percentage of CD4+ T cells expressed CD69 when stimulated with aAPC carrying anti-CD3 and anti-CD28 Abs on MDs, compared with stimulation by anti-CD3 coated beads (p < 0.03; Table I). Figure 2 shows FACS plots for a representative experiment. Comparable values in the production of IL-2 and expression of CD69 were found upon incubation of CD4+-sorted T cells with either aAPC loaded with anti-CD3 and anti-CD28 on MDs or with systems employing anti-CD3-coated plates and soluble anti-CD28 Abs (Table I). Engineered aAPC carrying the irrelevant Ab anti-CD19 alone on the MDs were used as controls and induced background T cell activation. Altogether, these data show that MDaAPC are at least as efficient as conventional methods in stimulating CD4+ T cells in an Ag-independent fashion.
|
|
We next compared the ability of MDaAPC and natural APC to stimulate a human T cell line in an Ag-specific fashion. To this end, we used the CH7C17 T cell line, which is specific for HA307319 peptide in the context of HLA DR1. We stimulated C7CH17 for 60 h with MDaAPC or natural APC loaded with the relevant Ag or with the irrelevant control peptide OVA323339.
Activation was measured as the percentage of CD4+ T cells induced to express the activation marker CD69. As shown in Table II, a sizable activation was achieved when compared with background or the irrelevant control. No significant differences in CD69 expression were found when MDaAPC stimulation was compared with stimulation of C7CH17 with homologous natural APC loaded with either the relevant peptide or the irrelevant controls (Table II).
|
Preclustering of T cell ligands on the membrane of the aAPC affects efficiency of T cell stimulation
Ag-specific activation of CD4+ human polyclonal T cells by different types of aAPC was studied in response to influenza peptide HA307319. FACS-sorted CD4+ T cells from HLA-DRB1*0701 and HLA-DRB1*1101 donors previously immunized with influenza vaccine were stimulated by using MHC-HA307319 class II complexes loaded on aAPC or organized in soluble tetramers. Intensity of responses was compared between aAPC with MHC-peptide complexes clustered on MDs or randomly distributed within the aAPC membrane. To compare aAPC with autologous APC-induced activation, total PBMC from both donors were stimulated in vitro for 60 h with HA307319 peptide at 10 µg/ml. Negative controls included sorted CD4+ T cells stimulated with MDaAPC containing either anti-CD19 or anti-CD28. MHC class II molecules used were either affinity-purified C-terminal-biotinylated DRB1*0701 obtained from a human B cell line expressing DRB1*0701 or recombinant biotinylated HLA-DRB1*1101. Percentages of CD69 and IL-2-positive cells were measured by FACS analysis on gated CD4+ T cells (Fig. 3 as summary of eight independent experiments and Fig. 4 showing FACS plots of one representative experiment). Expression of CD69 was significantly higher when aAPC containing MHC/HA307319 plus anti-CD28 organized into MDs were used, as compared with aAPC containing MHC/HA307319 in addition to anti-CD28 randomly distributed on the aAPC surface (Fig. 3a, p < 0.05). Similarly, IL-2 production was also significantly higher using aAPC containing MHC/HA307319 in addition to anti-CD28 organized into MDs vs aAPC containing MHC/HA307319 in addition to anti-CD28 randomly distributed on the aAPC surface (Fig. 3b, p < 0.009). The efficiency of both aAPC types in stimulating Ag-specific T cells was higher than the one obtained with soluble MHC/HA tetramers (Figs. 3 and 4), with or without anti-CD28 (3 mol of MHC/HA moles and 1 mol of anti-CD28 mole per mole of NA). No differences were observed between affinity-purified biotinylated DRB1*0701 and recombinant biotinylated HLA-DRB1*1101 in the efficiency of stimulating HA307319-specific CD4+ T cells (data not shown).
|
|
translocation
We then analyzed whether the supramolecular organization of T cell ligands on the surface of aAPC was associated with effective triggering of the physiological signaling pathways that lead to full T cell activation. To address this issue, we chose to correlate the level of translocation of PKC
to the T cell plasma membrane upon interaction with the two different types of aAPC. PKC
plays an essential role in T cell activation. Upon TCR engagement by its ligand, PKC
translocates from the cytosol to membrane lipid rafts clustering at the IS and colocalizing with TCR in the central core of the SMAC (1). PKC
translocation is also directly associated with IL-2 production and T cell activation. Hence, PKC
recruitment to the membrane could be correlated with physiological IS assembly and TCR signaling (33, 34). Translocation of PKC
was analyzed by confocal microscopy in FACS-sorted CD4+ T cells from influenza-immunized individuals after a 20-min incubation with various types of aAPC (Fig. 5). After cell fixation and permeabilization, endogenous PKC
was stained with a specific Ab. PKC
was homogeneously distributed in the cytosol in CD4+ T cells incubated with MDaAPC carrying an irrelevant Ab (anti-CD19) (Fig. 5a). Conversely, PKC
was translocated to discrete plasma membrane patches in CD4+ T cells incubated with MDaAPCs loaded with DRB1*0701/HA complexes alone (Fig. 5b) or with DRB1*0701/HA in combination with anti-CD28 on the MDaAPC (Fig. 5c). Incubation of CD4+ T cells with aAPC carrying HLADRB1*0701-HA complexes randomly distributed in the lipid bilayer (Fig. 5d) induced a lesser degree of PKC
translocation in membrane patches, underscoring the functional significance of membrane MDs. As previously shown (16), capping on the T cell membrane colocalized with the area of interaction between T cell and aAPC. Fig. 5e shows a T cell with PKC
stained red with Alexa Red and a cluster of aAPC stained with FITC-conjugated CTB (green).
|
translocation in the CD4+T cells incubated with aAPC or MDaAPC, we measured the area of PKC
patches formed at the T cell membrane level in a semiquantitative fashion. The relative area of PKC
translocation was measured by calculating the ratio of the total cell area to the area of PKC
patching and expressed as the percentage of the whole cell area. High-density pixel areas were identified by the software using standard settings. The ratios were calculated by MetaMorph Imaging System, version 3.5 (Universal Imaging). The area of each PKC
patch was expressed as percentage of the whole cell area. A comparable number of cells was analyzed in each condition. Evaluation was performed by an observer blinded to the identity of the samples. MDaAPC containing anti-CD19 and anti-CD28 were used as controls to define the background surface distribution of PKC
. PKC
patched areas were significantly wider when cells were stimulated with MHC-HA complexes loaded on MDs rather than when they were randomly distributed on the aAPC membrane (p < 0.001, Table III).
|
B and AP-1 transcription factors to specific consensus binding sites on IL-2 and CD69 gene promoters (35, 36). Since PKC
integrates downstream the TCR and CD28-derived activation signals by inducing activation and nuclear translocation of NF-
B and AP-1 (37, 38), the expression of genes involved in T cell activation might be correlated with the level of PKC
translocation at the IS. In fact, we found a statistically significant positive correlation between the PKC
capping area and the percentage of IL-2-producing CD4+ T cells (r = 0.85, p < 0.01). The percentage of CD4+ T cells expressing CD69 showed also a significantly positive correlation with PKC
capping area (r = 0.83, p < 0.04). | Discussion |
|---|
|
|
|---|
capping at the level of T-aAPC interaction areas. It is of interest to note that these correlations were obtained in entirely artificial systems by manipulating the level of organization of T cell ligands on the membrane, not their concentration, since amounts of reagents were identical between MD-aAPC and aAPC. The fact that we can control in an entirely artificial system molarity and relative concentrations of T cell ligands provides, in our opinion, a useful tool for basic science as well as medical applications. In our own experience (Ref. 26 and S. Albani, unpublished data), MDaAPC are an excellent tool to expand and modulate ex vivo Ag-specific T cells which are rare or otherwise difficult to grow. The use of MD-aAPC is particularly attractive for modulation ex vivo of T cell responses in therapy of cancer and infectious diseases. For instance, several clinical trials which use Drosophila-transfected or autologous Ag-loaded dendritic cells for ex vivo stimulation of T cells have shown promising preliminary results, particularly in melanoma and B cell lymphoma. Substantial problems have, however, plagued these attempts, in particular given the difficulties in standardization and the potential for xenoreactions in the case of nonhuman cells.
In summary, these data provide support for the concept that Ag-specific activation of polyclonal T cells may be positively affected by preclustering of T cell ligands. We propose here an entirely artificial system that enables the organization of relevant T cell ligands into membrane MDs and allows for manipulation of molarity, relative density, and affinity to achieve physiological Ag presentation.
| Disclosures |
|---|
|
|
|---|
| Acknowledgments |
|---|
| Footnotes |
|---|
1 This study was supported in part by National Institutes of Health Grants 5P50 AR44850-04, N01-AR-9-2241, 2R01 AI41721-05, and 1R01AR48084-01 and by a donation from Associazione Italiana Contro lArtrite (Milan, Italy). ![]()
2 F.G. and J.B. contributed equally to this work. ![]()
3 Address correspondence and reprint requests to Dr. Salvatore Albani, Department of Pediatrics, University of California, 9500 Gilman Drive, San Diego, CA 92093-0663. E-mail address: salbani{at}ucsd.edu ![]()
4 Abbreviations used in this paper: SMAC, supramolecular activation cluster; IS, immunological synapse; aAPC, artificial APC; CTB, cholera toxin B; NA, neutravidin; PKC, protein kinase C; HA, hemagglutinin; MD, microdomain; MDaAPC, aAPC cells with ligands organized into membrane MD; RT, room temperature. ![]()
Received for publication October 30, 2004. Accepted for publication December 21, 2004.
| References |
|---|
|
|
|---|
: a new essential superstar on the T-cell stage. Immunol. Today 21:567.[Medline]
to membrane rafts is required for T cell activation. Nat. Immunol. 2:556.[Medline]
B activation induced by T cell receptor/CD28 costimulation is mediated by protein kinase C-
. Proc. Natl. Acad. Sci. USA 97:3394.
is required for TCR-induced NF-
B activation in mature but not immature T lymphocytes. Nature 404:402.[Medline]
-NF-
B pathway in primary peripheral T cells. Int. Immunol. 15:655.This article has been cited by other articles:
![]() |
I. de Kleer, B. Vastert, M. Klein, G. Teklenburg, G. Arkesteijn, G. P. Yung, S. Albani, W. Kuis, N. Wulffraat, and B. Prakken Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network Blood, February 15, 2006; 107(4): 1696 - 1702. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |